Authors' response re. "May Silymarin be selectively considered for nonalcoholic fatty liver disease without elevated transaminases?"

Affiliations

¹ Division of Gastroenterology and Hepatology, First Department of Internal Medicine, AHEPA University Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece. Electronic address: giwrgoskalopitas@gmail.com.
² Division of Gastroenterology and Hepatology, First Department of Internal Medicine, AHEPA University Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.
³ Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.

Comment

Georgios Kalopitas et al. Nutrition. 2022 Jun.

. 2022 Jun:98:111510.

doi: 10.1016/j.nut.2021.111510. Epub 2021 Oct 10.

¹ Division of Gastroenterology and Hepatology, First Department of Internal Medicine, AHEPA University Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece. Electronic address: giwrgoskalopitas@gmail.com.
² Division of Gastroenterology and Hepatology, First Department of Internal Medicine, AHEPA University Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.
³ Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.

No abstract available

Keywords: Metabolic syndrome; NAFLD; Nonalcoholic fatty liver disease; Silymarin; Transaminases; Treatment.

Comment on

Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis.
Kalopitas G, Antza C, Doundoulakis I, Siargkas A, Kouroumalis E, Germanidis G, Samara M, Chourdakis M. Kalopitas G, et al. Nutrition. 2021 Mar;83:111092. doi: 10.1016/j.nut.2020.111092. Epub 2020 Nov 25. Nutrition. 2021. PMID: 33418491
May Silymarin be selectively considered for nonalcoholic fatty liver disease without elevated transaminases? Comment re. "Impact of Silymarin in individuals with nonalcoholic fatty liver disease: a systematic review and meta-analysis".
Liu L, Li Y, Qi X. Liu L, et al. Nutrition. 2022 Oct;102:111648. doi: 10.1016/j.nut.2022.111648. Epub 2022 Mar 2. Nutrition. 2022. PMID: 35577653 No abstract available.